Expression and significance of C-MYC and thioredoxin-interacting protein in prostate cancer

Objective To study the expression and significance of C-MYC and thioredoxin-interacting protein (TXNIP) in prostate cancer and benign prostatic hyperplasia. Methods 50 cases of prostate cancer tissues and 49 cases of benign prostatic hyperplasia tissues were selected. The immunohistochemistry method was used to detect the expression level of C-MYC and TXNIP, and the correlation with clinical data. Results The positive rate of C-MYC in prostate cancer tissues was 64.0% (32/50) while in benign prostatic hyperplasia tissues was 10.2% (5/49, P 7 group, the positive rate of C-MYC was statistically significant (P 7 group. In the Gleason score 7 group, 7 group. Overexpression of C-MYC was associated with downregulation of TXNIP (Spearman’s r=-0.306, P<0.05). Conclusion Overexpression of C-MYC and downregulation of TXNIP might be involved in the pathogenesis, development and degree of malignancy of prostate cancer. TXNIP is expected to be a potential therapeutic target for prostate cancer. Key words: Prostate cancer; C-MYC; Thioredoxin-interacting protein